GlassScriptPhysician profile
Alex Cheng
NPI 1275987836
$3,739.02
in general payments reported to CMS, 2019-2025
24 companies · $1,498 in 2025
The $1,498 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.95 · 2021: $282 · 2022: $428 · 2023: $709 · 2024: $810 · 2025: $1,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,016.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $962.19 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $415.77 | 2021-2025 | Rexulti |
| Alkermes, INC. | $371.70 | 2022-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $311.55 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $245.92 | 2024-2025 | Ingrezza |
| Neos Therapeutics, LP | $182.56 | 2023-2025 | Adzenys Xr-Odt, Exxua |
| Axsome Therapeutics, INC. | $178.82 | 2023-2025 | Auvelity, Sunosi |
| Almatica Pharma LLC | $163.75 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Lundbeck LLC | $160.06 | 2022-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $107.44 | 2024-2025 | Fanapt, Hetlioz, Ponvory |
| Takeda Pharmaceuticals U.S.A., INC. | $103.50 | 2021-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $93.27 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $87.25 | 2021-2022 | |
| Bausch Health US, LLC | $62.43 | 2022-2025 | Aplenzin |
| Abbott Laboratories | $60.34 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $54.32 | 2025 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.43 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $27.79 | 2023 | Quviviq |
| Corium, LLC | $27.35 | 2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $21.28 | 2024 | Qelbree |
| Acadia Pharmaceuticals INC | $17.63 | 2025 | Nuplazid |
| Sage Therapeutics, LLC | $16.05 | 2024 | |
| Janssen Pharmaceuticals, INC | $15.67 | 2021 | |
| Allergan, INC. | $12.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.